COVID-19 Impact analysis

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. This highly contagious disease, caused by a virus , is a  severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is transmitted from one person to another. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a pandemic on March 11, 2020.

Pharmaceutical and biotech companies along with governments across  the globe work to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. According to NCBI, out of 116 duchenne muscular dystrophy patients one patient found to be positive for Covid-19 infection. Moreover, commonly used drugs such as Corticosteroids have witnessed a dramatic increase in demand for the management of patients with duchenne muscular dystrophy with COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as there is a shortage of these drugs in many developed countries. Thus, the pharmaceutical and biotechnology industry is expected to experience a significant growth in the future owing to the demand for corticosteroids drugs for COVID-19. This in turn is expected to have a significant impact on the duchenne muscular dystrophy market.

Top Impacting Factors

• Factors that drive the growth of duchenne muscular dystrophy market are increase in awareness campaigns about duchenne muscular dystrophy disorder,  development of mutation-specific therapies, increase in prevalence of duchenne muscular dystrophy market, rise in number of product pipeline, increase in number of therapies such as Exondys51, Translarna, launch exon skipping technologies, introduction of corticosteroid based anti-inflammatory treatment .
• Furthermore, increase in healthcare expenditure; availability of skilled professionals; collaborations & partnerships between key players to facilitate drug development; rise in R&D activities to improve quality of drugs; introduced new medicine such as Ataluren to treat children with duchenne muscular dystrophy aged five or older are some factors, which boost the market growth for duchenne muscular dystrophy market.
• However, high cost of treatment is expected to hinder the market growth.
• Contrarily, favorable reimbursement policies and support from government for regulatory approval present new pathways in the industry.

Market Trends

New Product Launches to Flourish the Market

In February 2021, Sarepta Therapeutics has received DA approval for Amondys 45 (casimersen injection), it is an antisense oligonucleotide for the treatment of Duchenne Muscular Dystrophy patients. 

In August 2020, NS Pharma, Inc. launched Viltepso (viltolarsen injection) for the treatment of DMD patients who confirmed mutation of Duchenne Muscular Dystrophy gene which is amenable to skipping of exon 53.

In December 2019, Tahio Pharmaceutical launched TAS-205, it is hematopoietic prostaglandin D synthase (HPGDS) inhibitor for the treatment of DMD. TAS-205 exacerbates the inflammatory response in patients of DMD.

Key Benefits of the Report

• This study presents the analytical depiction of the duchenne muscular dystrophy industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the duchenne muscular dystrophy market share.
• The current market is quantitatively analyzed from 2021 to 2030 to highlight the growth scenario  of the duchenne muscular dystrophy market.
• Porter’s Five Forces analysis illustrates the potency of buyers & suppliers in the market. 
• The report provides a detailed duchenne muscular dystrophy market analysis based on competitive intensity and the competition that will take shape in coming years

Questions Answered in the Duchenne Muscular Dystrophy Report

• Who are the leading market players active in the duchenne muscular dystrophy market?
• What are the current trends that will influence the market in the next few years?
• What are the driving factors, restraints, and opportunities in the duchenne muscular dystrophy market?
• What are the future projections that would help in taking further strategic steps?
• What is "duchenne muscular dystrophy "?
• What is "duchenne muscular dystrophy" market prediction in the future?
• Who are the leading global players in the "duchenne muscular dystrophy" market?
• What are the current trends and predicted trends of “duchenne muscular dystrophy” market?
• What are the key benefits of the "duchenne muscular dystrophy "market report?